Advertisement
Australia markets close in 5 hours 44 minutes
  • ALL ORDS

    7,855.90
    -43.00 (-0.54%)
     
  • ASX 200

    7,598.90
    -43.20 (-0.57%)
     
  • AUD/USD

    0.6416
    -0.0009 (-0.14%)
     
  • OIL

    82.55
    -0.18 (-0.22%)
     
  • GOLD

    2,389.20
    -8.80 (-0.37%)
     
  • Bitcoin AUD

    98,234.94
    +3,000.42 (+3.15%)
     
  • CMC Crypto 200

    1,303.43
    +417.89 (+46.77%)
     
  • AUD/EUR

    0.6029
    -0.0001 (-0.02%)
     
  • AUD/NZD

    1.0874
    -0.0001 (-0.01%)
     
  • NZX 50

    11,789.11
    -46.93 (-0.40%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     
  • NIKKEI 225

    37,576.53
    -503.17 (-1.32%)
     

Is AbbVie a Buy?

Is AbbVie a Buy?

Drugmaker AbbVie (NYSE: ABBV) is one of the largest healthcare stocks in the world, with a market cap of over $250 billion. AbbVie last reported its earnings in July. Humira remains key to AbbVie's business for now, generating $5.4 billion this past quarter, nearly three times the $1.8 billion Skyrizi and Rinvoq generated.